Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...

When Blenrep was initially approved, its label carried a black box warning for ocular toxicity. GSK said eye-related side effects were generally manageable in the clinical trial and resolved with ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

"This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection," said GSK's chief scientific officer Tony Wood. "Adults aged 50-59 with ...

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 38,541.57 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

GSK’sGSK-0.34%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...